Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and GLENN LARKIN

Axsome Therapeutics Stock Sees Relative Strength Rating Jump To 92

Axsome Therapeutics had its Relative Strength (RS) Rating upgraded from 89 to 92 Thursday.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.

Over 100 years of market history reveals that the top-performing stocks often have an RS Rating of at least 80 at the beginning of a new price run.

See How IBD Helps You Make More Money In Stocks

Axsome Therapeutics stock is now considered extended and out of buy range. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line. Of course, with Uptrend Under Pressure, be careful out there.

Regarding top and bottom line numbers, Axsome Therapeutics has posted two quarters of rising earnings growth. Sales growth has been less impressive, coming in at 0% last quarter. Next earning report is scheduled for May 10.

The company earns the No. 107 rank among its peers in the Medical-Biomed/Biotech industry group. Pacira Pharmaceuticals, Amphastar Pharmaceutcls and Regeneron Pharmaceutical are among the top 5 highly rated stocks within the group.

 

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.